Hemostatic and metabolic variables in women with polycystic ovary syndrome.
OBJECTIVE
To study whether a previously demonstrated increased morbidity in cardiovascular disease (CVD) and diabetes mellitus in women with polycystic ovary syndrome (PCOS) is associated with certain hemostatic variables that are known to be markers for CVD.


METHODS
The study was a trans-sectional follow-up study from a cohort of women with PCOS.


METHODS
The women with PCOS were recruited from hospital clinics and referents were randomized from a population study of women from the same area.


METHODS
The investigation involved 28 women aged 43 to 62 years diagnosed to have PCOS on ovarian histopathology at wedge resection 25 to 34 years previously and 56 referents who were matched by age and body mass index.


METHODS
In connection with a clinical investigation, the hemostatic variables fibrinogen, von Willebrand factor antigen, factor VII procoagulant activity, factor VII antigen, and plasminogen activator inhibitor as well as the metabolic variables serum insulin and serum triglycerides were assayed.


RESULTS
There was a strong positive correlation between serum concentrations of triglyceride, basal insulin, and abdominal obesity on the one hand, and plasminogen activator inhibitor, fibrinogen, and von Willebrand factor on the other, among women with PCOS as well as among referents. There were significantly higher mean concentrations of fibrinogen and factor VII:Ag among referents, but the mean values of most hemostatic variables studied showed no differences between the groups.


CONCLUSIONS
Women with an altered metabolic profile were also found to have affected hemostatic factors, but PCOS in itself did not seem to influence them.
Dahlgren
E
E
Sahlgrenska Hospital, Faculty of Medicine, University of Göteborg, Sweden.
Janson
P O
PO
Johansson
S
S
Lapidus
L
L
Lindstedt
G
G
Tengborn
L
L
D000328:Adult; D000941:Antigens / Q000032:analysis; D005167:Factor VII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006487:Hemostasis; D006801:Humans; D006973:Hypertension / Q000150:complications; D007328:Insulin / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000378:metabolism*; D012044:Regression Analysis; D014280:Triglycerides / Q000097:blood; D014841:von Willebrand Factor / Q000032:analysis
D000941:Antigens; D007328:Insulin; D015849:Plasminogen Inactivators; D014280:Triglycerides; C042580:factor VII clotting antigen; C031500:factor VII related antigen; D014841:von Willebrand Factor; D005167:Factor VII; D005340:Fibrinogen